UBS raises DaVita stock price target to $287 on reimbursement outlook

UBS raised its DaVita price target to $287 from $270 and maintained a Buy rating; the stock was cited at $187.50, up 57% over the past year. DaVita expects an effective 2027 Medicare update of 1.5%–2%, about 50 basis points above the proposed update but below its cost trend; each 100-basis-point increase is worth approximately $30 million annually. Separately, the company beat third-quarter estimates with adjusted EPS of $3.82 versus $3.55 and revenue of $3.58 billion versus $3.51 billion, though shares fell after hours amid concerns about costs and long-term growth.

Analysis

The key issue is not the higher analyst target; it is whether reimbursement growth can keep pace with treatment costs. The expected 2027 Medicare update remains below management’s cost trend, leaving structural margin pressure even if the final rate is modestly better than proposed. The stated sensitivity implies a 50 bp improvement is roughly $15 million of annual revenue, but that is not equivalent to earnings upside and should be sized against verified cost inflation and treatment volumes.

The fixed phosphate-binder payment improves near-term predictability, but it also reduces responsiveness to changing drug economics: generic conversion and contracting could support margins, while higher input costs or unfavorable physician-led drug mix could erode them. The temporary DefenCath payment is a favorable but nonrecurring contribution for DaVita because it has no corresponding drug cost; its roll-off creates a 2027 comparison headwind. Other dialysis operators, including Fresenius Medical Care, face the broader reimbursement/cost mismatch, so DaVita’s relative advantage depends on execution rather than the policy headline.

Near term, the sharp prior share-price appreciation and the reported post-earnings decline despite a beat argue against chasing a target-price upgrade. Over 1–3 months, track final reimbursement rules, treatment volumes, and management’s cost-per-treatment trajectory. Over 6–18 months, the thesis hinges on whether contracting and generic conversion offset below-cost reimbursement updates. The UBS target is an analyst view, not evidence that this margin bridge is secured.

Key Decisions for Investors

• Avoid adding aggressively after the rally. For investors seeking exposure, consider a modest, staged DVA long on weakness, contingent on management maintaining its cost-control outlook and treatment volumes; do not underwrite the analyst target as a base case.
• Use the next reimbursement-rule update and quarterly disclosures as entry gates: verify the full-year effective Medicare update, cost per treatment, utilization, and drug mix. The stated Medicare sensitivity is a useful revenue check, not an earnings forecast.
• Falsify the constructive view if the effective update falls below management’s stated range, cost inflation widens the reimbursement gap, or utilization/drug mix offsets generic and contracting savings. Reassess if margin guidance is cut or treatment volumes weaken.
• Treat the DefenCath contribution as temporary rather than recurring earnings power; compare 2027 results with and without its expected roll-off before extrapolating growth.